SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Supriya Lifescience Ltd

BSE: 543434 NSE: SUPRIYA ISIN: INE07RO01027
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Supriya Lifescience Ltd belong to?
Supriya Lifescience Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Supriya Lifescience Ltd a good quality company?
Supriya Lifescience Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Supriya Lifescience Ltd undervalued or overvalued?
Supriya Lifescience Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Supriya Lifescience Ltd a good buy now?
Supriya Lifescience Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Supriya Lifescience Ltd?
Supriya Lifescience Ltd revenue growth is 22.1% for FY-2025 , which is above its 5 year CAGR of 17.5% , indicating faster growth.
Q.2 Gross Profit margin of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Gross profit margin which is the profit after deduction of direct costs, is 34.4% for FY-2025 , which is in line with its 5 year median of 34.4% , indicating stable margins.
Q.3 Operating Profit Margin of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 37.46% for FY-2025 , which is in line with its 5 year median of 37.46% indicating stable margins.
Q.4 Net Profit Margin of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Net Profit Margin is 26.99% for FY-2025 , is in line with with its 5 year median of 26.99%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 34.4 34.4
Operating Profit Margin 37.46 37.46
Net Profit Margin 26.99 26.99
Q.5 Return on Asset of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Return on Asset is 18.42%, which is in line with its 5 year historical median of 18.42%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Return on equity is 20.74% for FY-2025 , which is in line with its historical median of 20.74%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Return on capital employed is 27.63% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Cash conversion cycle is 47 days, below its historical median of 51 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.77 0.77
ROE 20.74 20.74
ROCE 27.63 27.63
Cash Conversion Cycle 47 days 51 days
Q.9 Debt to Equity ratio of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Supriya Lifescience Ltd?
Supriya Lifescience Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Supriya Lifescience Ltd?
Promoters hold 68.30% of the Supriya Lifescience Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Supriya Lifescience Ltd vs industry peers?
Supriya Lifescience Ltd revenue CAGR is 17.45% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 696.5 137.1
Gross Profit 239.4 15.1
Operating Profit 261 16
Net Profit 188 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.77 0.8
ROE 20.74 8.91
ROCE 27.63 11.59
Cash Conversion Cycle (days) 47.09 76

Valuation & price assessment

Q.1 Stock return of Supriya Lifescience Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 44.58% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - 44.6% -12.9%
Q.3 Valuation ratios of Supriya Lifescience Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 27.28 24.18 40.28
Price to Book 4.47 3.09 2.77
Price to Sales 6.87 4.58 2.65
EV to EBITDA 18 12.05 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×